AI 411: March 2025
Your monthly roundup of AI announcements is here.
Francis Scialabba
Your monthly roundup of AI announcements is here.
Francis Scialabba
Welcome back to AI 411, a monthly roundup of artificial intelligence (AI) announcements from across the healthcare industry.
This month, the following were named on Fast Company’s most innovative healthcare companies list:
In other news, here is your roundup of health-related AI updates from March.
Artera. On March 11, Santa Barbara, California-based Artera announced patient enrollment in PROSTATE-IQ, a Phase 3 clinical trial to test if its technology works for men who experience prostate cancer recurrence after receiving a prostatectomy. Participants in the trial will undergo the company’s ArteraAI Prostate Test, which uses AI to personalize treatment by figuring out the risk of cancer spread and identifying patients who could reduce hormone therapy use.
Gleamer. The French company that created BoneView, which uses AI to scan X-rays to detect fractures and got FDA approval in March 2023, announced FDA clearance on March 25 for a new product called ChestView, made to “detect anomalies” in chest X-rays.
Rush/Suki. Chicago-based Rush University System for Health expanded its partnership with AI scribe maker Suki on March 3 to use its clinical note-taking product throughout the health system, which includes the 671-bed Rush University Medical Center. The partnership includes plans to develop an AI “dictation feature” that can work directly in electronic health record system Epic.
Silna Health. Menlo Park, California-based Silna Health announced on March 25 that it has raised $22 million in Series A funding, bringing its total to $27 million. The company uses AI to manage prior authorization with insurance companies, check benefits, and verify patient eligibility. The funding round was led by Bain Capital Ventures and Accel.
Taxo. The San Francisco-based health tech company that helps clinicians speed up administrative paperwork raised $5 in seed funding, according to a March 27 announcement. The company’s funding was led by venture capitalist funds Y Combinator, General Catalyst, and Character.
